Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 12/20 | 0.55 |
| ▸ | RAB9A | P51151 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216734 | 0.86 | KDM4E (0.62) | KMT2APOLBTDP1NPC1RAB9A | |
| SCHEMBL12124464 | 0.84 | DAO (0.61) | KMT2APOLBTDP1DAONPC1 | |
| SCHEMBL279582 | 0.81 | KMT2A (0.62) | KMT2APOLBTDP1DAONPC1 | |
| SCHEMBL15296784 | 0.80 | POLB (0.71) | KMT2APOLBTDP1DAONPC1 | |
| SCHEMBL16674874 | 0.79 | KMT2A (0.56) | KMT2APOLBTDP1DAONPC1 | |
| SCHEMBL16659333 | 0.78 | KDM4E (0.70) | KMT2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL16659334 | 0.78 | KDM4E (0.70) | KMT2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL16198921 | 0.78 | KDM4E (0.70) | KMT2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL13473838 | 0.78 | KDM4E (0.55) | KMT2APOLBTDP1NPC1RAB9A | |
| SCHEMBL14625227 | 0.78 | KDM4E (0.59) | KMT2APOLBTDP1DAONPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220135558-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3336090-B1 | IRAK4 INHIBITOR AND USE THEREOF | BEIJING HANMI PHARMACEUTICAL CO LTD (CN) | 2020-07-22 | — | — | EP | disclosed |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-17 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | ENTPD5, NUDT15, ITPA | KMT2A 2360/4885POLB 390/4885TDP1 395/4885 |
| US-20220135558-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE | ENTPD5, NUDT15, ITPA | KMT2A 2360/4885POLB 390/4885TDP1 395/4885 |
| US-10590129-B2 | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases | MAP4K2, MAP3K3, MAP3K1 | KMT2A 2285/4885POLB 2221/4885TDP1 1635/4885 |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | ENTPD5, NUDT1, ITPA | KMT2A 2307/4885POLB 296/4885TDP1 354/4885 |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | KMT2A 3083/4885POLB 1708/4885TDP1 3564/4885 |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | KMT2A 1859/4885POLB 4262/4885TDP1 4052/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | KMT2A 4126/4885POLB 3118/4885TDP1 3507/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | KMT2A 4126/4885POLB 3118/4885TDP1 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.